LOGIN  |  REGISTER
Viking Therapeutics

Sonida Senior Living to Participate in Citi’s 30th Annual Global Property CEO Conference

February 17, 2025 | Last Trade: US$22.05 0.31 1.43

DALLAS / Feb 17, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Citi’s 30th Annual Global Property CEO Conference on Monday, March 3rd through Wednesday, March 5th at the Diplomat Resort & Spa Hollywood in Florida.

Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative.

In addition, Mr. Ribar is scheduled to participate in a moderated roundtable discussion on Wednesday, March 5th from 8:10 a.m. – 8:45 a.m. EST.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page